A robust ex vivo model for evaluation of induction of apoptosis by rhTRAIL in combination with proteasome inhibitor MG132 in human premalignant cervical explants

International Journal of Cancer

Volumn 123, Issue 6, 2008, Pages 1457-1465

  Hougardy, Brigitte M T ^a   Reesink Peters, Nathalie ^a   Van Den Heuvel, Fiona A J ^a   Ten Hoor, Klaske A ^a   Hollema, Harry ^a   De Vries, Elisabeth G E ^a   De Jong, Steven ^a   Van Der Zee, Ate G J ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apoptosis; Cervical explants; Proteasome inhibitor; rhTRAIL

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; PROTEASOME INHIBITOR; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; DRUG POTENTIATION; DRUG SCREENING; DRUG SENSITIVITY; EX VIVO STUDY; EXPERIMENTAL MODEL; EXPLANT; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; PRECANCER; PRIORITY JOURNAL; REPRODUCIBILITY; UTERINE CERVIX BIOPSY; UTERINE CERVIX CARCINOMA IN SITU;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CULTURE TECHNIQUES; CELLS, CULTURED; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LEUPEPTINS; PRECANCEROUS CONDITIONS; RECOMBINANT PROTEINS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UTERINE CERVICAL NEOPLASMS;

EID: 49749094091     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23684     Document Type: Article

References (38)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001;94:153-6.
2. Mitchell MF, Tortolero-Luna G, Wright T, Sarkar A, Richards-Kortum R, Hong WK, Schottenfeld D. Cervical human papillomavirus infection and intraepithelial neoplasia: a review. J Natl Cancer Inst Monogr 1996;21:17-25.
3. Crane JM. Pregnancy outcome after loop electrosurgical excision procedure: a systematic review. Obstet Gynecol 2003;102:1058-62.
4. zur Hausen H. Papillomavirus infections - a major cause of human cancers. Biochim Biophys Acta 1996;1288:F551-F78.
5. Isacson C, Kessis TD, Hedrick L, Cho KR. Both cell proliferation and apoptosis increase with lesion grade in cervical neoplasia but do not correlate with human papillomavirus type. Cancer Res 1996;56:669-74.
6. ter Harmsel B, Kuijpers J, Smedts F, Jeunink M, Trimbos B, Ramaekers F. Progressing imbalance between proliferation and apoptosis with increasing severity of cervical intraepithelial neoplasia. Int J Gynecol Pathol 1997;16:205-11.
7. Lee JS, Kim HS, Jung JJ, Lee MC, Park CS. Angiogenesis, cell proliferation and apoptosis in progression of cervical neoplasia. Anal Quant Cytol Histol 2002;24:103-13.
8. Reesink-Peters N, Hougardy BMT, van den Heuvel FAJ, Ten Hoor KA, Hollema H, Boezen HM, de Vries EG, de Jong S, van der Zee AG. Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol 2005;96:705-13.
9. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer 2002;2:420-30.
10. Das H, Koizumi T, Sugimoto T, Chakraborty S, Ichimura T, Hasegawa K, Nishimura R. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer 2000;82:1682-8.
11. Leithauser F, Dhein J, Mechtersheimer G, Koretz K, Bruderlein S, Henne C, Schmidt A, Debatin KM, Krammer PH, Moller P. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. Lab Invest 1993;69:415-29.
12. Ryu HS, Chang KH, Chang SJ, Kim MS, Joo HJ, Oh KS. Expression of TRAIL (TNF-related apoptosis-inducing ligand) receptors in cervical cancer. Int J Gynecol Cancer 2000;10:417-24.
13. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996;271:12687-90.
14. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, Sutherland GR, Smith TD, Rauch C, Smith CA. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995;3:673-82.
15. Leverkus M, Neumann M, Mengling T, Rauch CT, Brocker EB, Krammer PH, Walczak H. Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000;60:553-9.
16. Scheffner M, Whitaker NJ. Human papillomavirus-induced carcinogenesis and the ubiquitin-proteasome system. Semin Cancer Biol 2003;13:59-67.
17. He Q, Huang Y, Sheikh MS. Proteasome inhibitor MG132 upregulates death receptor 5 and cooperates with Apo2L/TRAIL to induce apoptosis in Bax-proficient and -deficient cells. Oncogene 2004;23:2554-8.
18. Johnson TR, Stone K, Nikrad M, Yeh T, Zong WX, Thompson CB, Nesterov A, Kraft AS. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003;22:4953-63.
19. Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ, Murphy WJ. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 2003;102:303-10.
20. Leverkus M, Sprick MR, Wachter T, Mengling T, Baumann B, Serfling E, Brocker EB, Goebeler M, Neumann M, Walczak H. Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturation. Mol Cell Biol 2003;23:777-90.
21. Hougardy BM, Maduro JH, van der Zee AG, de Groot DJ, van den Heuvel FA, de Vries EG, de Jong S. Proteasome inhibitor MG132 sensitizes HPV-positive human cervical cancer cells to rhTRAIL-induced apoptosis. Int J Cancer 2006;118:1892-900.
22. Kurman RJ, Norris HJ, Wilkinson E. Tumors of the cervix, vagina and vulva; Tumors of the cervix. In: Rosai J, editor. Atlas of tumor pathology, 3rd edn. Washington, DC: Armed Forces Institute of Pathology, 1992;37-139.
23. Palacio J, Souberbielle BE, Shattock RJ, Robinson G, Manyonda I, Griffin GE. In vitro HIV1 infection of human cervical tissue. Res Virol 1994;145:155-61.
24. Mourits MJE, Hollema H, de Vries EGE, Ten Hoor KA, Willemse PH, Van Der Zee AG. Apoptosis and apoptosis-associated parameters in relation to tamoxifen exposure in postmenopausal endometrium. Hum Pathol 2002;33:341-6.
25. Sadarangani A, Kato S, Espinoza N, Lange S, Llados C, Espinosa M, Villalón M, Lipkowitz S, Cuello M, Owen GI. TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis 2007;12:73-85.
26. Lu X, Arbiser JL, West J, Hoedt-Miller M, Sheridan A, Govindarajan B, Harral JW, Rodman DM, Fouty B. Tumor necrosis factor-related apoptosis-inducing ligand can induce apoptosis in subsets of premalignant cells. Am J Pathol 2004;165:1613-20.
27. Hague A, Hicks DJ, Hasan F, Smartt H, Cohen GM, Paraskeva C, MacFarlane M. Increased sensitivity to TRAIL-induced apoptosis occurs during the adenoma to carcinoma transition of colorectal carcinogenesis. Br J Cancer 2005;92:736-42.
28. Aguilar-Lemarroy A, Gariglio P, Whitaker NJ, Eichhorst ST, zur Hausen H, Krammer PH, Rösl F. Restoration of p53 expression sensitizes human papillomavirus type 16 immortalized human keratinocytes to CD95-mediated apoptosis. Oncogene 2002;21:165-75.
29. Tolcher AW, Mita M, Patnaik A, Rowinsky EK, Corey A, Fleming M, Fox NL, Weiner LM, Meropol NJ, Cohen R. A phase 1 and pharmacokinetic study of HGS-ETR1 (TRM-1), a human monoclonal agonist-antibody to TRAIL-R1, in patients with advanced solid tumors. J Clin Oncol 2004;S14:3060.
30. Georgakis GV, Humphreys R, Li Y, Andreeff M, O'Brien S, Younes M, Carbone A, Albert V, Younes A. Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Br J Haematol 2005;30:501-10.
31. Herbst RS, Mendolson DS, Ebbinghaus S, Gordon MS, O'Dwyer P, Lieberman G, Ing J, Kurzrock R, Novotny W, Eckhardt G. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis-inducing protein in patients with advanced cancer. J Clin Oncol 2006;18S:3013.
32. Richardson PG. A review of the proteasome inhibitor bortezomib in multiple myeloma. Expert Opin Pharmacother 2004;5:1321-31.
33. Paramore A, Frantz S. Bortezomib. Nat Rev Drug Discov 2003;2:611-2.
34. Walker F, Adle-Biassette H, Madelenat P, Henin D, Lehy T. Increased apoptosis in cervical intraepithelial neoplasia associated with HIV infection: implication of oncogenic human papillomavirus, caspases, and Langerhans cells. Clin Cancer Res 2005;11: 2451-8.
35. Zanotti S, Fisseler-Eckhoff A, Mannherz HG. Changes in the topological expression of markers of differentiation and apoptosis in defined stages of human cervical dysplasia and carcinoma. Gynecol Oncol 2003;89:376-84.
36. Grossmann J. Molecular mechanisms of "detachment-induced apoptosis-Anoikis". Apoptosis 2002;7:247-60.
37. Koomstra JJ, de Jong S, Hollema H, de Vries EGE, Kleibeuker JH. Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. Crit Rev Oncol Hematol 2003;45:37-53.
38. Jalving M, de Jong S, Koomstra JJ, Boersma-van Ek W, Zwart N, Wesseling J, de Vries EG, Kleibeuker JH. TRAIL induces apoptosis in human colorectal adenoma cell lines and human colorectal adenomas. Clin Cancer Res 2006;12:4350-6.